FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

We examined 6 different FMS-like tyrosine kinase-3 (FLT3) inhibitors (lestaurtinib, midostaurin, AC220, KW-2449, sorafenib, and sunitinib) for potency against mutant and wild-type FLT3, as well as for cytotoxic effect against a series of primary blast samples obtained from patients with acute myeloi...

Full description

Saved in:
Bibliographic Details
Main Authors: Pratz, Keith W., Sato, Takashi, Murphy, Kathleen M., Stine, Adam, Rajkhowa, Trivikram, Levis, Mark
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2010
Subjects:
Myeloid Neoplasia
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2826764/
https://ncbi.nlm.nih.gov/pubmed/20007803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-09-242859
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items